We consider ourselves a one-stop shop for the generics pharmaceutical industry, says Frances Zipp, President and CEO of AAM associate member Lachman Consultants.
Manufacturers might come to us for regulatory expertise, but they stay with us for science/technology or compliance, so they don’t have to bounce around.
- From the Lachman Consultants blog: Remote Inspection Now a Reality, But Will It Solve the Backlog of Inspections?
Leon Lachman, PhD, an analytical chemist, founded the Long Island-based firm in 1978. Initially, much of the focus was on compliance, principally with the generic industry, and it has become one of the most reputable firms in the consulting industry, working across all areas of pharmaceutical and medical device technology and compliance. Over the years, its portfolio expanded to regulatory and other areas, with the addition of senior former FDA veterans.
We’ve been with AAM from the beginning, says Zipp,
and we believe in the mission of improving access to high-quality, affordable medicines. Today, Lachman Consultants handles scientific issues and emerging technologies (such as gene therapy) for generic and brand-name manufacturers large and small, as well as manufacturers of medical devices.
Zipp and her colleagues frequently appear at events for AAM and other associations such as the International Society for Pharmaceutical Engineering (ISPE).
- May 6, 11:00 a.m.: Zipp moderates the ISPE webinar 503B Compounding Pharmacies: Principles, GMPs & Case Studies.
They appreciate the chance to learn from and network with leaders in the generics and biosimilar industries. “It’s a very innovative group of people,” she says. “Not enough people understand that what happens in generic facilities is truly state of the art.”
By Jewel Smith, AAM Senior Director, Operations
Published on May 21, 2021